StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3013% below fair value
$2.01−0.06 (-2.66%)

Close on Nov 16, 2026Market cap $159.04MP/E 16.8Yield –

Niagen Bioscience EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Niagen Bioscience's EV/EBITDA was 9.3× on Nov 11, 2026, against 24.6× a year earlier. Over the last 2 years it ranged from 9.3× to 885.1×, with a median of 24.6×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20269.3×−13.6
2025Dec 31, 202522.9×−806.9
2024Dec 31, 2024829.8×–

More Niagen Bioscience figures

See a number that looks wrong?